Takeda introduces living bacteria cocktail for treatment of inflammatory bowel disease

The product has been developed by US Finch Therapeutics Co., and Takeda has obtained a global exclusive license. Applications are in ulcerative colitis and other diseases.

Takeda news release, April 6, 2017

Takeda introduces living bacteria cocktail for treatment of inflammatory bowel disease
Scroll to top